Cited by 284Prostate Cancer Treatment and ResearchChromatin Remodeling and CancerCancer Genomics and Diagnostics

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer

Open access

Parolia, Abhijit, Cieslik, Marcin, Chu, Shih-Chun, Xiao, Lanbo, Ouchi, Takahiro, Zhang, Yuping, Wang, Xiaoju, Vats, Pankaj, Cao, Xuhong, Pitchiaya, Sethuramasundaram, Su, Fengyun, Wang, Rui, Feng, Felix Y., Wu, Yi-Mi, Lonigro, Robert J., Robinson, Dan R., Chinnaiyan, Arul M.·2019·Nature

DOI 10.1038/s41586-019-1347-4PMC PMC6661908

Open this paper in CoChat — free account

Abstract

Abtract Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland 1,2. FOXA1 is frequently mutated in hormone-receptor-driven prostate, breast, bladder and salivary-gland tumours 3-8. However, it is unclear how FOXA1 alterations affect the development of cancer, and FOXA1 has previously been ascribed both tumour-suppressive 9-11 and oncogenic 12-14 roles. Here we assemble an aggregate cohort of 1,546 prostate cancers and show that FOXA1 alterations fall into three structural classes that diverge in clinical incidence and genetic co-alteration profiles, with a collective prevalence of 35%. Class-1 activating mutations originate in early prostate cancer without alterations in ETS or SPOP, selectively recur within the wing-2 region of the DNA-binding forkhead domain, enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen-receptor program of prostate oncogenesis. By contrast, class-2 activating mutations are acquired in metastatic prostate cancers, truncate the C-terminal domain of FOXA1, enable dominant chromatin binding by increasing DNA affinity and-through TLE3 inactivation-promote metastasis driven by the WNT pathway. Finally, class-3 genomic rearrangements are enriched in metastatic prostate cancers, consist of duplications and translocations within the FOXA1 locus, and structurally reposition a conserved regulatory element-herein denoted FOXA1 mastermind (FOXMIND)-to drive overexpression of FOXA1 or other oncogenes. Our study reaffirms the central role of FOXA1 in mediating oncogenesis driven by the androgen receptor, and provides mechanistic insights into how the classes of FOXA1 alteration promote the initiation and/or metastatic progression of prostate cancer. These results have direct implications for understanding the pathobiology of other hormone-receptor-driven cancers and rationalize the co-targeting of FOXA1 activity in therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1347-4

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
MEME SUITE: tools for motif discovery and searching
Bailey, T. L., Boden, M., Buske, F. A., Frith, M., Grant, C. E., Clementi, L., Ren, J., Li, W. W., & Noble, W. S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp335 · Cited by 10,648
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155

Show all 60 references

Research works printed but not linked: 1

Smyth, G. K., McCarthy, D. J. & Smyth, G. K. in Bioinformatics and Computational Biology Solutions Using R and Bioconductor (eds Dudoit, S. & Carey, V. J.) 397–420 (Springer, New York, 2005).

Sorted by citations

Items 101–200 of 284

ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L
Feng, W., Ladewig, E., Lange, M., Salsabeel, N., Zhao, H., Lee, Y. S., Gopalan, A., Luo, H., Kang, W., Fan, N., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02289-w · Cited by 25
FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression
Su, Y., Zhang, Y., Zhao, J., Zhou, W., Wang, W., Han, B., & Wang, X. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03730-3 · Cited by 22
Self-citation
SPOP-mutant prostate cancer: Translating fundamental biology into patient care
Bernasocchi, T., & Theurillat, J.-P. P. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.024 · Cited by 22
Modeling prostate cancer: What does it take to build an ideal tumor model?
Mai, C., Chin, K., Foong, L. C., Pang, K.-L., Yu, B., Shu, Y., Chen, S., Cheong, S., & Chua, C. W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215794 · Cited by 22
ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Kodgule, R., Goldman, J. W., Monovich, A. C., Saari, T. W., Aguilar, A. R., Hall, C. N., Rajesh, N., Gupta, J., Chu, A., Ye, L., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0224 · Cited by 29
Self-citation
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential
Kneppers, J., Severson, T., Siefert, J. C., Schol, P. J., Joosten, S. E. P., Yu, I. P. L., Huang, C.-C. F., Morova, T., Altıntaş, U. B., Giambartolomei, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35135-2 · Cited by 22
The role of FOXA family transcription factors in glucolipid metabolism and NAFLD
Yu, C., Li, X., Zhao, Y., & Hu, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1081500 · Cited by 25
Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
Zucker, M., Perry, M., Gould, S. I., Elkrief, A., Safonov, A. M., Thummalapalli, R., Mehine, M. M., Chakravarty, D., Brannon, A. R., Ladanyi, M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.11.010 · Cited by 19
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components
Soundararajan, R., Viscuse, P. V., Pilie, P. G., Liu, J., Logotheti, S., Laberiano-Fernández, C., Lorenzini, D., Hoang, A. G., Lü, W., Soto, L. M. S., et al. (2022) · Cancers · doi:10.3390/cancers14133233 · Cited by 21
Clinical implications of genomic alterations in metastatic prostate cancer
Sumiyoshi, T., Chi, K. N., & Wyatt, A. W. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00308-x · Cited by 21
Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K. J., Hugh-White, R., van der Kwast, T. H., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2056 · Cited by 21
Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression
Angappulige, D. H., Mahajan, N. P., & Mahajan, K. N. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.004 · Cited by 21
Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes
Jillson, L. K., Yette, G. A., Laajala, T. D., Tilley, W. D., Costello, J. C., & Cramer, S. D. (2021) · Cancers · doi:10.3390/cancers13133272 · Cited by 20
Epigenetics-Based Diagnostic and Therapeutic Strategies: Shifting the Paradigm in Prostate Cancer
Clermont, P. (2023) · Epigenomics · doi:10.2217/epi-2023-0045 · Cited by 19
FOXA1 prevents nutrients deprivation induced autophagic cell death through inducing loss of imprinting of IGF2 in lung adenocarcinoma
Li, J., Zhang, Y., Wang, L., Li, M., Yang, J., Chen, P., Zhu, J., Li, X., Zeng, Z., Li, G., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05150-8 · Cited by 19
Self-citation
TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer
Singh, R., Meng, H., Shen, T., Lumahan, L. E. V., Nguyen, S., Shen, H., Dasgupta, S., Qin, L., Karri, D., Zhu, B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218229120 · Cited by 19
A Review of Prostate Organogenesis and a Role for iPSC-Derived Prostate Organoids to Study Prostate Development and Disease
Buskin, A., Singh, P., Lorenz, O., Robson, C. N., Strand, D. W., & Heer, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313097 · Cited by 24
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
Miller, C. D., Likasitwatanakul, P., Toye, E., Hwang, J. H., & Antonarakis, E. S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2405103 · Cited by 15
Potential role of glucosamine-phosphate N-acetyltransferase 1 in the development of lung adenocarcinoma
Zhang, S., Zhang, H., Li, H., Guo, J., Wang, J., & Zhang, L. (2021) · Aging · doi:10.18632/aging.202604 · Cited by 16
Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression
Hu, L., Chen, X., Narwade, N. P., Lim, M. G. L., Chen, Z., Tennakoon, C., Guan, P., Chan, U. I., Zhao, Z., Deng, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02026-7 · Cited by 16
FOXA1 /2 depletion drives global reprogramming of differentiation state and metabolism in a human liver cell line and inhibits differentiation of human stem cell‐derived hepatic progenitor cells
Warren, I., Moeller, M. M., Guiggey, D., Chiang, A., Maloy, M. H., Ogoke, O., Groth, T., Mon, T., Meamardoost, S., Liu, X., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101506rrr · Cited by 17
Prostate cancer stem cell dynamics in the evolution of drug resistance
Zhang, X., Zhang, X., Deng, X., Cao, J., Bao, Q., Wang, H., Chen, D., & Tang, H. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002611 · Cited by 15
Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer
Chukhu, M., Dahiya, U. R., & Heemers, H. V. (2025) · Oncogene · doi:10.1038/s41388-025-03573-z · Cited by 17
Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer
Leach, D. A., Fernandes, R. C., & Bevan, C. L. (2022) · Endocrine Oncology · doi:10.1530/eo-22-0065 · Cited by 16
SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1
Wang, Z., Petricca, J., Liu, M., Zhang, S., Chen, S., Li, M., Besschetnova, A., Patalano, S. C., Venkataramani, K., Siegfried, K. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220472120 · Cited by 15
Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors
Mumphrey, M. B., Hosseini, N., Parolia, A., Geng, J., Zou, W., Raghavan, M., Chinnaiyan, A. M., & Cieslik, M. P. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112965 · Cited by 15
Self-citation
Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling
Tabibian, M., Moghaddam, F. S., Motevaseli, E., & Ghafouri‐Fard, S. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01833-1 · Cited by 15
A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levelsPreprint
Zhou, J., Cattoglio, C., Shao, Y., Tirumala, H. P., Vetralla, C., Bajikar, S. S., Li, Y., Chen, H., Wang, Q., Wu, Z., et al. (2023) · Genes & Development · doi:10.1101/gad.350733.123 · Cited by 15
To bind or not to bind: Cistromic reprogramming in prostate cancer
Shen, M., Demers, L.-K., Bailey, S. D., & Labbé, D. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.963007 · Cited by 15
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity
Choi, J. E., Qiao, Y., Kryczek, I., Yu, J., Gurkan, J. K., Bao, Y., Gondal, M. N., Tien, J. C.-Y., Maj, T., Yazdani, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48931-9 · Cited by 14
Self-citation
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer
Manzar, N., Ganguly, P., Khan, U. K., & Ateeq, B. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.004 · Cited by 14
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models
Bao, Y., Chang, Y., Tien, J. C.-Y., Cruz, G., Yang, F., Mannan, R., Mahapatra, S., Paturu, R., Cao, X., Su, F., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci193745 · Cited by 13
Self-citation
Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer
Celada, S. I., Li, G., Celada, L. J., Lu, W., Kanagasabai, T., Feng, W., Cao, Z., Salsabeel, N., Mao, N., Brown, L. K., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13497 · Cited by 13
Self-citation
Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma
Yuen, J. G., Hwang, G., Fesler, A. T., Intriago, E., Pal, A. S., Ojha, A., & Ju, J. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200769 · Cited by 13
MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
German, B., Alaiwi, S. A., Ho, K.-L., Nanda, J. S., Fonseca, M. A., Burkhart, D. L., Sheahan, A. V., Bergom, H. E., Morel, K. L., Beltran, H., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0069 · Cited by 18
The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Bao, Y., Cruz, G., Zhang, Y., Qiao, Y., Mannan, R., Hu, J., Yang, F., Gondal, M. N., Shahine, M., Kang, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0435 · Cited by 16
Self-citation
Updates on Molecular and Biochemical Development and Progression of Prostate Cancer
Fahmy, O., Alhakamy, N. A., Rizg, W. Y., Bagalagel, A. A., Alamoudi, A. J., Aldawsari, H. M., Khateb, A. M., Eldakhakhny, B. M., Fahmy, U. A., Abdulaal, W. H., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215127 · Cited by 13
In Vivo Application of CRISPR/Cas9 Revealed Implication of Foxa1 and Foxp1 in Prostate Cancer Proliferation and Epithelial Plasticity
Cai, H., Agersnap, S. N., Sjøgren, A., Simonsen, M. K., Blaavand, M. S., Jensen, U. V., & Thomsen, M. K. (2022) · Cancers · doi:10.3390/cancers14184381 · Cited by 13
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Hwang, J., Likasitwatanakul, P., Deshmukh, S. K., Wu, S., Kwon, J. J., Toye, E., Moline, D., Evans, M. G., Elliott, A., Passow, R., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3471 · Cited by 12
The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Yamaguchi, T. N., Houlahan, K. E., Zhu, H., Kurganovs, N. J., Livingstone, J. M., Fox, N. S., Yuan, J., Penington, J. S., Jung, C.-H., Schwarz, T., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0882 · Cited by 13
Integrative Epigenome Map of the Normal Human Prostate Provides Insights Into Prostate Cancer Predisposition
Wang, T., Song, J., Qu, M., Gao, X., Zhang, W., Wang, Z., Zhao, L., Wang, Y., Li, B., Li, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.723676 · Cited by 12
Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer
Duan, Y., Cui, C., Qiu, C., Sun, G., Wang, X., Wang, P., Ye, H., Dai, L., & Shi, J. (2022) · Disease Markers · doi:10.1155/2022/6657820 · Cited by 12
Self-citation
CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer
Xiang, R. R., Lee, S.-A., Tyndall, C. F., Bhatia, A. R., Yin, J., Singler, C., Hauk, B. J., Kipp, M. P., & Takeda, D. Y. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115312 · Cited by 11
Roles and correlation of FOXA1 and ZIC1 in breast cancer
Zhang, Y.-W., Ma, J., Shi, C.-T., Han, W., Gao, X., Zhou, M.-H., Ding, H.-Z., & Wang, H. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100559 · Cited by 11
Self-citation
Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach
Machado, C. B., da Cunha, L. S., Maués, J. H. D. S., Pessoa, F. M. C. D. P., de Oliveira, M. B., Ribeiro, R. M., Lopes, G. S., de Moraes, M. O., de Moraes, M. E. A., Khayat, A. S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105486 · Cited by 13
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Li, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02388-8 · Cited by 10
Self-citation
EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells
Huttunen, J., Aaltonen, N., Helminen, L., Rilla, K. J., & Paakinaho, V. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05209-z · Cited by 10
Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access
Fenton, S. E., VanderWeeler, D. J., Rebbeck, T. R., & Chen, D. L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433138 · Cited by 12
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non–small cell lung, prostate, and breast cancers
Goglia, A. G., Alshalalfa, M., Khan, A., Isakov, D., Hougen, H. Y., Swami, N. S., Kannikal, J., McBride, S. M., Gomez, D. R., Punnen, S., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae224 · Cited by 10
FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma
Ge, J., Liu, Y., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010091 · Cited by 10
The bromodomain inhibitor JQ1 up-regulates the long non-coding RNA MALAT1 in cultured human hepatic carcinoma cells
Choi, H. I., An, G. Y., Yoo, E., Baek, M., Binas, B., Chai, J. C., Lee, Y. S., Jung, K. H., & Chai, Y. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-11868-4 · Cited by 10
Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients
Abouhashem, N. S., Harb, O. A., Elwan, A., Zaitoun, M., & Saraya, Y. S. (2022) · Polish Journal of Pathology · doi:10.5114/pjp.2022.120097 · Cited by 10
LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance
Zhang, H., & Zheng, Y. (2023) · Oncology Letters · doi:10.3892/ol.2023.13720 · Cited by 10
Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies
Hwang, K. W., Yun, J. W., & Kim, H. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115823 · Cited by 12
Cancer regulatory variation
Hennessey, R. C., & Brown, K. M. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.11.010 · Cited by 10
The ADRB1 (Adrenoceptor Beta 1) and ADRB2 genes significantly co-express with commonly mutated genes in prostate cancer.
Lehrer, S. P., & Rheinstein, P. H. (2020) · PubMed · Cited by 10
Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
Arruabarrena-Aristorena, A., & Toska, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924808 · Cited by 11
Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer
Eickhoff, N., Bergman, A. M., & Zwart, W. T. (2022) · Endocrinology · doi:10.1210/endocr/bqac153 · Cited by 10
Interruption of aberrant chromatin looping is required for regenerating RB1 function and suppressing tumorigenesis
Wen, X., Ding, T., Li, F., Fan, J., Fan, X., Jia, R., & Zhang, H. (2022) · Communications Biology · doi:10.1038/s42003-022-04007-2 · Cited by 10
Functionally analyzing the important roles of hepatocyte nuclear factor 3 (FoxA) in tumorigenesis
Gao, B. X., Xie, W., Wu, X., Wang, L., & Guo, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188365 · Cited by 9
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
Yu, W., Zhang, T., Wang, B., Pan, J. G., Jin, S., Fang, B., Gu, W., Qin, X., Dai, B., Lin, G., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13511 · Cited by 9
Dynamic phosphorylation of FOXA1 by Aurora B guides post-mitotic gene reactivation
Zhang, T., Liu, S., Durojaye, O. A., Xiong, F., Fang, Z., Ullah, T., Fu, C., Sun, B., Jiang, H., Xia, P., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114739 · Cited by 11
Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer
Ye, J., Xie, Y., Wang, J., Wu, R., Li, D., Yoo, K. H., Wusiman, D., Cho, W. C., Lyu, Z., & Feng, D. (2026) · Research · doi:10.34133/research.1128 · Cited by 12
Elevated FOXA1 Expression Indicates Poor Prognosis in Liver Cancer due to Its Effects on Cell Proliferation and Metastasis
Liu, Z., Wang, Y., Aizimuaji, Z., Ma, S., & Xiao, T. (2022) · Disease Markers · doi:10.1155/2022/3317315 · Cited by 9
Sex-associated early-life viral innate immune response is transcriptionally associated with chromatin remodeling of type-I IFN-inducible genes
Malinczak, C., Fonseca, W., Mire, M. M., Parolia, A., Chinnaiyan, A. M., Rasky, A. J., Morris, S. B., Yagi, K., Bermick, J., & Lukacs, N. W. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.06.002 · Cited by 9
Self-citation
Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
Cussenot, O., Cancel‐Tassin, G., Rao, S. R., Woodcock, D. J., Lamb, A. D. G., Mills, I. G., & Hamdy, F. C. (2023) · British Journal of Urology · doi:10.1111/bju.16120 · Cited by 10
Label-free quantitative proteomic analysis identifies the oncogenic role of FOXA1 in BaP-transformed 16HBE cells
Wang, Y., Li, L., Hao, M., Fu, D., Chen, J., Zhou, C., Fu, J., Yao, B., Chang, B., & Zhao, P. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115160 · Cited by 9
Susceptibility-Associated Genetic Variation in NEDD9 Contributes to Prostate Cancer Initiation and Progression
Han, D. G., Owiredu, J. N., Healy, B. M., Li, M., Labaf, M., Steinfeld, J. S., Patalano, S. C., Gao, S., Liu, M., Macoska, J. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3042 · Cited by 9
Targeting LSD1 and FOXA1 in prostate cancer
Omarjee, S., & Carroll, J. S. (2020) · Nature Genetics · doi:10.1038/s41588-020-0702-6 · Cited by 8
The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis
Ma, J., Cai, M., Mo, Y., Fried, J. S., Tan, X., Ma, Y., Chen, J., Han, S., & Xu, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658230 · Cited by 8
Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progressionPreprint
Uusi-Mäkelä, J., Afyounian, E., Tabaro, F., Häkkinen, T., Lussana, A., Shcherban, A., Annala, M., Nurminen, R., Kivinummi, K. K., Tammela, T. L. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.08.287268 · Cited by 11
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer
Broderick, A. J., Pan, E., Li, J., Chu, A., Hwang, C., Barata, P. C., Cackowski, F. C., Labriola, M., Ghose, A., Bilen, M. A., et al. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00869-1 · Cited by 7
Assessing next-generation sequencing-based computational methods for predicting transcriptional regulators with query gene sets
Lu, Z., Xiao, X., Zheng, Q., Wang, X., & Xu, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae366 · Cited by 7
Self-citation
Alterations in transcriptional networks in cancer: the role of noncoding somatic driver mutations
Doane, A. S., & Elemento, O. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101919 · Cited by 8
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer
McSweeney, S. T., Bergom, H. E., Prizment, A. E., Halabi, S., Sharifi, N., Ryan, C. J., & Hwang, J. H. (2022) · Endocrine Oncology · doi:10.1530/eo-22-0058 · Cited by 7
A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery
Tian, J., Chi, C., Bian, G., Guo, F., Wang, X., & Yu, B. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13499 · Cited by 7
Self-citation
The role of transcription factors in prostate cancer progression
Lee, J., & Lee, Y. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100193 · Cited by 7
Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer
Shuai, Y., & Huang, H. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.06.001 · Cited by 6
Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer
Formaggio, N., Sgrignani, J., Thillaiyampalam, G., Lorenzi, C., Cassanmagnago, G. A., Coazzoli, M., Costanzo, F., Uebelhart, Y., Bossi, D., Cassiano, D. C., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116324 · Cited by 6
Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications
Kneppers, J., Bergman, A. M., & Zwart, W. T. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_15 · Cited by 6
Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer
Choi, S. H., Pan, E., Elliott, A., Beltran, H., Panian, J. A., Jamieson, C. A. M., Bagrodia, A., Rose, B. S., Herchenhorn, D., Heath, E. I., et al. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0395 · Cited by 6
Pioneer factors outline chromatin architecture
Gómora‐García, J. C., & Furlan-Magaril, M. (2025) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2025.102480 · Cited by 7
SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression
Eteleeb, A. M., Quigley, D. A., Zhao, S. G., Pham, D., Yang, R., Dehm, S. M., Luo, J. R., Feng, F. Y.-C., Dang, H. X., & Maher, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-71168-7 · Cited by 6
Self-citation
High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
Sheta, H., hafez, A. A. E., Saif, M., Elsergany, A. R., emam, D. A., & Abdelrazik, M. M. (2021) · Pathologica · doi:10.32074/1591-951x-217 · Cited by 6
Identification of Transcription Factors Regulating SARS-CoV-2 Tropism Factor Expression by Inferring Cell-Type-Specific Transcriptional Regulatory Networks in Human Lungs
Tong, H., Chen, H., & Williams, C. (2022) · Viruses · doi:10.3390/v14040837 · Cited by 6
FOXA1 ‐induced LINC00621 promotes lung adenocarcinoma progression via activating the TGF ‐β signaling pathway
Wei, J., Yu, H., Liu, T., Wang, Z., Lang, C., & Pan, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14986 · Cited by 6
Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression
Hong, Z., Xu, C., Zheng, S., Wang, X., Tao, Y., Tan, Y., Lin, G., Wu, D., & Ye, D. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01682-w · Cited by 7
Self-citation
Emerging role of pioneer transcription factors in targeted ERα positive breast cancer
Pavithran, H., & Kumavath, R. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00031 · Cited by 6
Transcription factors direct epigenetic reprogramming at specific loci in human cancers
Jiang, H., & Li, G. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1234515 · Cited by 5
Case report: Squamous cell carcinoma of the prostate-a clinicopathological and genomic sequencing-based investigation
Zhang, C., Jia, Y., & Kong, Q. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611343 · Cited by 5
The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells
Budreika, A., Phoenix, J. T., Kostlan, R. J., Deegan, C. D., Ferrari, M. G., Young, K., Fanning, S., & Kregel, S. (2025) · Cancers · doi:10.3390/cancers17020306 · Cited by 4
Systematic Analysis of Cellular Signaling Pathways and Therapeutic Targets for SLC45A3:ERG Fusion-Positive Prostate Cancer
Kim, J., Hwang, K. W., Lee, H. J., & Kim, H. S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111818 · Cited by 5
TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
Anstine, L. J., Majmudar, P. R., Aponte, A., Singh, S., Zhao, R., Weber-Bonk, K. L., Abdul‐Karim, F. W., Valentine, M. J., Seachrist, D. D., Grennel-Nickelson, K. E., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3133 · Cited by 5
The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities
Huang, R., Bornman, R. M. S., Stricker, P. D., Brum, I. S., Mutambirwa, S. B. A., Jaratlerdsiri, W., & Hayes, V. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-57566-1 · Cited by 5
Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer
Wyatt, A. W., & Vandekerkhove, G. R. (2020) · Société Internationale d’Urologie Journal · doi:10.48083/vsoo5322 · Cited by 5
Chromatin accessibility profiles of castration-resistant prostate cancers reveal novel subtypes and therapeutic vulnerabilitiesPreprint
Tang, F., Wang, S., Wong, C. K., Lee, C. J., Cohen, S. M., Park, J., Hill, C. E., Eng, K., Bareja, R., Han, T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.26.355925 · Cited by 4
Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer
Felice, D. D., Alaimo, A., Bressan, D., Genovesi, S., Marmocchi, E., Annesi, N., Beccaceci, G., Dalfovo, D., Cutrupi, F., Medaglia, S., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00335-y · Cited by 4
Phase Separation in Chromatin Organization and Human Diseases
Zhai, Z., Meng, F., Kuang, J., & Pei, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115156 · Cited by 4
HIF1α-PHD1-FOXA1 Axis Orchestrates Hypoxic Reprogramming and Androgen Signaling Suppression in Prostate Cancer
Liang, L., Dong, D., Sun, J., Zhang, Q., Yang, X., Zhang, P., & Wei, G.-H. (2025) · Cells · doi:10.3390/cells14131008 · Cited by 6
Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Hosseini, N., Mannan, R., Rebernick, R. J., Su, F., Wang, R., Cao, X., Lako, A., Mellacheruvu, D., Hu, J., Alumkal, J. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3687 · Cited by 5
Self-citation

Authors: Parolia, A., Cieslik, M., Chu, S.-C., Xiao, L., Ouchi, T., Zhang, Y., Wang, X., Vats, P., Cao, X., Pitchiaya, S., Su, F., Wang, R., Feng, F. Y., Wu, Y.-M., Lonigro, R. J., Robinson, D. R., & Chinnaiyan, A. M.
Affiliations: University of Michigan (US)
Howard Hughes Medical Institute (US)
University of California, San Francisco (US)
Corresponding author: Chinnaiyan, Arul M.
ORCID: Parolia, Abhijit
Cieslik, Marcin
Xiao, Lanbo
Zhang, Yuping
Wang, Xiaoju
Vats, Pankaj
Cao, Xuhong
Pitchiaya, Sethuramasundaram
Su, Fengyun
Wang, Rui
Feng, Felix Y.
Wu, Yi-Mi
Robinson, Dan R.
Chinnaiyan, Arul M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-06-26
Volume: 571
Issue: 7765
Pages: 413-418
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1347-4
PMC: PMC6661908
OpenAlex: W2955719861
Cited by: 284
References: 60
Citations by year: 2026: 25 · 2025: 40 · 2024: 34 · 2023: 44 · 2022: 47 · 2021: 50 · 2020: 35 · 2019: 9
FWCI: 25.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Howard Hughes Medical Institute
National Cancer Institute (F99CA245825, R35CA231996, U01CA214170, P50CA186786)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: FOXA1, prostate cancer, activating mutations, androgen receptor, chromatin binding, metastasis, Wnt signaling, TLE3, genome rearrangement, ETS transcription factors, SPOP, carcinogenesis
MeSH terms: Protein Domains, Chromatin, Humans, Male, Models, Molecular, Mutation, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Genome, Human, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Hepatocyte Nuclear Factor 3-alpha, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks